Halberd Corporation 2Q23 CEO Letter - Seite 2

THE LOOK AHEAD

Pre-clinical testing of Halberd's patent-pending nasal spray intended to counter the effects of TBI are progressing and will continue through the 3^rd and possibly into the 4^th quarter, depending on the findings at each step in the research project. This product offers the potential of self-administration by military personnel in the field, and should be of intense interest to contact sports participants due to its safe and obstructive nature in blocking the cascade of excess neurodegenerative elements.

Youngstown State University researchers will continue testing using Halberd's patented technology for eradication of antigens associated with cancer. YSU already demonstrated success in eradicating the principal cancer disease antigens CTLA-4, PD-1, PDL-1 and tumor necrosis factor -alpha (TNF-a). The only remaining primary antigen is BTLA, which will be tested near-term.

Halberd will submit proposal abstracts to the US Department of Defense Advanced Research Projects Agency (DARPA) which will outline Halberd's potential to treat various diseases and conditions.

Halberd will explore the potential of applying its extracorporeal cancer eradication methodology in the treatment of certain cancers common to both humans and pets, starting with dogs.

Halberd will continue to explore potential non-dilutive funding opportunities, consistent with its charter.

Halberd will continue to update the public and loyal stockholders on events as they occur on these and other projects that arise.

SUMMARY

The second quarter presented many challenges and opportunities for applying our patented and patent-pending technologies. We are continuing to expand our intellectual property and push the boundaries of the technology to develop safe and effective alternative treatments to conventional injected or ingested drug therapies.

We want to express our appreciation for the dedication and hard work of our scientists, university research partners and Halberd personnel.

Sincerely,

William A. Hartman
Chairman, President & CEO
HALBERD CORPORATION
[e-mail];
[e-mail]
www.halberdcorporation.com
Twitter:@HalberdC

About Halberd Corporation.

Halberd Corporation (the "Company") is an innovative biotech company focused on developing treatments through its acquired exclusive licenses, patents, and provisional patent applications for illnesses including and limited to; PTSD, CTE, cancer, blood-borne, and cerebrospinal fluid related diseases. To learn more, please visit https://halberdcorporation.com.

Halberd secured exclusive worldwide rights to three issued patents and filed 21 related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

SOURCE: Halberd Corporation

View source version on accesswire.com:
https://www.accesswire.com/769280/Halberd-Corporation-2Q23-CEO-Letter


The Halberd Stock at the time of publication of the news with a fall of -1,04 % to 0,010USD on Nasdaq OTC stock exchange (20. Juli 2023, 02:10 Uhr).